Nivalis Therapeutics Inc (NASDAQ:NVLS) shares are collapsing nearly 60% after the biotech firm’s cavosonstat’s Phase II proof-of-concept trial in F508del homozygous cystic fibrosis …
Nivalis Therapeutics Inc (NASDAQ:NVLS) investors are heading for the hills after the drug maker reported that the Phase 2 study of cavosonstat as an …
Tuesday turned out to be a nightmare for Nivalis Therapeutics Inc (NASDAQ:NVLS) investors, after the drug maker reported that its Phase 2 study of …
